SBTX vs. MIRM, SDGR, MTSR, BHVN, BLTE, NAMS, SUPN, JANX, ARWR, and HRMY
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Mirum Pharmaceuticals (MIRM), Schrödinger (SDGR), Metsera (MTSR), Biohaven (BHVN), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), Supernus Pharmaceuticals (SUPN), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics vs.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
Silverback Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
74.9% of Silverback Therapeutics shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Mirum Pharmaceuticals received 114 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
Silverback Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. Silverback Therapeutics' return on equity of -29.62% beat Mirum Pharmaceuticals' return on equity.
Mirum Pharmaceuticals currently has a consensus price target of $58.20, suggesting a potential upside of 51.68%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Silverback Therapeutics.
In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than Silverback Therapeutics. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 2 mentions for Silverback Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Silverback Therapeutics' score of 0.67 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.
Mirum Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Summary
Mirum Pharmaceuticals beats Silverback Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SBTX) was last updated on 4/21/2025 by MarketBeat.com Staff
Buy SBTX Stock Free SBTX Stock Alerts